SUMMARY OF PEER-REVIEWED CLINICAL DATA*

Reduction in Retained Blood

Sirch, et al:	43% Reduction	JTCVS[1]
St. Onge, et al:	42% Reduction	JCTS[3]
Baribeau, et al:	58% Reduction	JCTS[2]
Kelly, et al:	91% Reduction	Presented[7]

Reduction in Postoperative Atrial Fibrillation**

St. Onge, et al:	18% Reduction	JCTS[3]
St. Onge, et al:	31% Reduction	JTCVS[4]
Baribeau, et al:	32% Reduction	JCTS[2]
Sirch, et al:	33% Reduction	JTCVS[1]

**Retained Blood has been shown to contribute to the occurrence of post operative atrial fibrillation (POAF). These studies showed a reduction in POAF which correlated with a reduction in retained blood in patients with PleuraFlow. These findings suggest that use of PleuraFlow can reduce retained blood, which may contribute to reduced risk of POAF in some patients.

Reduction in Length of Stay

St. Onge, et al:	1 Day	JTCVS[4]
Baribeau, et al:	1 Day	JCTS[2]

Reduction in Re-exploration for Bleeding

Grieshaber, et al:	59% Reduction	ATS[5]
Maltais, et al:	65% Reduction	ASAIO[6]
Baribeau, et al:	70% Reduction	JCTS[2]
St. Onge, et al:	72% Reduction	JCTS[3]
Kelly, et al:	100% Reduction	Presented[7]

1 – Sirch, et al   J Thoracic & Cardiovascular Surgery
2 – Baribeau, et al J Cardiothoracic Surgery
3 – St. Onge, et al J Cardiothoracic Surgery
4 – St. Onge, et al J Thoracic & Cardiovascular Surgery
5 – Grieshaber, at al Annals of Thoracic Surgery
6 – Maltais, et al   American Society for Artificial Internal Organs
7 – Kelly, et al Presented at ECTSS 2020

*Studies include both retrospective observational assessments and prospective trials, supported by ClearFlow. Results could be impacted by variations in study methodologies, institutional protocols used in treating patients, and other factors. ClearFlow products are not therapeutic devices. Please see full publications at www.clearflow.com for additional information.

ML274-C